• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

预测肾细胞癌合并静脉瘤栓患者总生存和癌症特异性生存的列线图：一项基于人群的研究

Nomograms for Predicting Overall Survival and Cancer-Specific Survival of Patients With Renal Cell Carcinoma and Venous Tumor Thrombus: A Population-Based Study.

作者信息

Yang Lin, Fu Bin

机构信息

Department of Urology, The First Affiliated Hospital of Nanchang University, Nanchang, China.

出版信息

Front Surg. 2022 Jun 8;9:929885. doi: 10.3389/fsurg.2022.929885. eCollection 2022.

DOI:10.3389/fsurg.2022.929885
PMID:36034346
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9411105/
Abstract

BACKGROUND

To provide better prognostic information for patients with renal cell carcinoma (RCC) combined with venous tumor thrombus (VTT). In turn, guide patients' families and doctors to formulate plans for follow-up treatment and follow-up. We developed nomograms to predict cancer-specific survival (CSS) and overall survival (OS).

METHODS

A total of 2961 cases were included in this study. Through univariate and multivariate Cox proportional hazard regression analysis, independent risk factors affecting CSS and OS were screened out, and then a nomogram was drawn based on the screened variables.

RESULTS

Independent risk factors affecting CSS include: tumor size (HR = 1.05), histology (HR = 1.75), grade (HR = 1.94), N staging (HR = 2.06), and M staging (HR = 2.87). The median survival time for CSS was 106 months. Independent risk factors for OS include age (HR = 1.60), tumor size (HR = 1.04), histology (HR = 1.60), grade (HR = 1.68), N staging (HR-1.99), M staging (HR = 2.45). The median survival time for OS is 67 months.

CONCLUSIONS

The nomogram based on independent risk factors affecting CSS and OS can well predict the prognosis of renal cell carcinoma with venous tumor thrombus.

摘要

背景

为肾细胞癌（RCC）合并静脉瘤栓（VTT）患者提供更好的预后信息。进而指导患者家属和医生制定后续治疗及随访计划。我们开发了列线图来预测癌症特异性生存（CSS）和总生存（OS）。

方法

本研究共纳入2961例病例。通过单因素和多因素Cox比例风险回归分析，筛选出影响CSS和OS的独立危险因素，然后基于筛选出的变量绘制列线图。

结果

影响CSS的独立危险因素包括：肿瘤大小（HR = 1.05）、组织学类型（HR = 1.75）、分级（HR = 1.94）、N分期（HR = 2.06）和M分期（HR = 2.87）。CSS的中位生存时间为106个月。影响OS的独立危险因素包括年龄（HR = 1.60）、肿瘤大小（HR = 1.04）、组织学类型（HR = 1.60）、分级（HR = 1.68）、N分期（HR = 1.99）、M分期（HR = 2.45）。OS的中位生存时间为67个月。

结论

基于影响CSS和OS的独立危险因素的列线图能够很好地预测伴有静脉瘤栓的肾细胞癌的预后。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0007/9411105/06bc2166185f/fsurg-09-929885-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0007/9411105/b6b581ad42a2/fsurg-09-929885-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0007/9411105/2388fe860ba8/fsurg-09-929885-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0007/9411105/74dd7cf708f6/fsurg-09-929885-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0007/9411105/0878c719e8f9/fsurg-09-929885-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0007/9411105/23933697cb9a/fsurg-09-929885-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0007/9411105/7ef5afd01e06/fsurg-09-929885-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0007/9411105/40f139d756fd/fsurg-09-929885-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0007/9411105/06bc2166185f/fsurg-09-929885-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0007/9411105/b6b581ad42a2/fsurg-09-929885-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0007/9411105/2388fe860ba8/fsurg-09-929885-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0007/9411105/74dd7cf708f6/fsurg-09-929885-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0007/9411105/0878c719e8f9/fsurg-09-929885-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0007/9411105/23933697cb9a/fsurg-09-929885-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0007/9411105/7ef5afd01e06/fsurg-09-929885-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0007/9411105/40f139d756fd/fsurg-09-929885-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0007/9411105/06bc2166185f/fsurg-09-929885-g008.jpg

相似文献

1
Nomograms for Predicting Overall Survival and Cancer-Specific Survival of Patients With Renal Cell Carcinoma and Venous Tumor Thrombus: A Population-Based Study.预测肾细胞癌合并静脉瘤栓患者总生存和癌症特异性生存的列线图：一项基于人群的研究
Front Surg. 2022 Jun 8;9:929885. doi: 10.3389/fsurg.2022.929885. eCollection 2022.
2
Prognostic indicators for survival in renal cell carcinoma with venous thrombus and development of predictive nomograms.肾细胞癌伴静脉血栓形成患者生存的预后指标及预测列线图的制定
Transl Androl Urol. 2022 Oct;11(10):1374-1388. doi: 10.21037/tau-22-128.
3
Prognostic Factors and a Nomogram Predicting Overall Survival and Cancer-Specific Survival for Patients with Collecting Duct Renal Cell Carcinoma.预测肾集合管细胞癌患者总生存和癌症特异性生存的预后因素和列线图。
Biomed Res Int. 2021 Nov 11;2021:6736008. doi: 10.1155/2021/6736008. eCollection 2021.
4
Development and validation of a Surveillance, Epidemiology, and End Results (SEER)-based prognostic nomogram for predicting survival in gastric cancer with multi-organ metastases.基于监测、流行病学和最终结果（SEER）数据库的预测多器官转移胃癌患者生存的预后列线图的开发与验证
Transl Cancer Res. 2022 Jun;11(6):1534-1551. doi: 10.21037/tcr-21-2569.
5
A prognostic model of patients with ovarian mucinous adenocarcinoma: a population-based analysis.卵巢黏液性囊腺癌患者的预后模型：基于人群的分析。
J Ovarian Res. 2022 Feb 16;15(1):26. doi: 10.1186/s13048-022-00958-6.
6
Prognostic nomograms and Aggtrmmns scoring system for predicting overall survival and cancer-specific survival of patients with kidney cancer.用于预测肾癌患者总生存期和癌症特异性生存期的预后列线图及Aggtrmmns评分系统。 需注意，原文中的“Aggtrmmns”可能有误，不太明确其准确含义。
Cancer Med. 2020 Apr;9(8):2710-2722. doi: 10.1002/cam4.2916. Epub 2020 Feb 22.
7
A Clinical Model of Bone Angiosarcoma Patients: A Population-based Analysis of Epidemiology, Prognosis, and Treatment.骨血管肉瘤患者的临床模型：基于人群的流行病学、预后和治疗分析。
Orthop Surg. 2020 Dec;12(6):1652-1662. doi: 10.1111/os.12803. Epub 2020 Sep 10.
8
Prognostic nomogram for hepatocellular carcinoma with radiofrequency ablation: a retrospective cohort study.肝癌射频消融治疗的预后列线图：一项回顾性队列研究。
BMC Cancer. 2021 Jun 29;21(1):751. doi: 10.1186/s12885-021-08505-0.
9
Multicenter Study of Controlling Nutritional Status (CONUT) Score as a Prognostic Factor in Patients With HIV-Related Renal Cell Carcinoma.多中心研究控制营养状况（CONUT）评分作为 HIV 相关肾细胞癌患者的预后因素。
Front Immunol. 2021 Nov 30;12:778746. doi: 10.3389/fimmu.2021.778746. eCollection 2021.
10
Survival nomogram for patients with bone metastatic renal cell carcinoma: A population-based study.基于人群的研究：患有骨转移肾细胞癌患者的生存预测图。
Int Braz J Urol. 2021 Mar-Apr;47(2):333-349. doi: 10.1590/S1677-5538.IBJU.2020.0195.

引用本文的文献

1
A comparison of open, laparoscopic, and robotic radical nephrectomy with tumor thrombectomy from the intercontinental collaboration on renal cell carcinoma.来自肾细胞癌洲际合作组织的开放性、腹腔镜及机器人辅助根治性肾切除术联合肿瘤血栓切除术的比较
J Robot Surg. 2025 Jun 4;19(1):269. doi: 10.1007/s11701-025-02424-z.
2
[Risk factors for massive hemorrhage after radical nephrectomy and removal of venous tumor thrombus].[根治性肾切除术及静脉瘤栓切除术后大出血的危险因素]
Beijing Da Xue Xue Bao Yi Xue Ban. 2023 Oct 18;55(5):825-832. doi: 10.19723/j.issn.1671-167X.2023.05.008.

本文引用的文献

1
Oncologic Outcomes of Renal Cell Carcinoma Patients Undergoing Radical Nephrectomy and Venous Thrombectomy: Prospective Follow-Up from a Single Center.接受根治性肾切除术和静脉血栓切除术的肾细胞癌患者的肿瘤学结局：来自单一中心的前瞻性随访
J Oncol. 2022 Mar 17;2022:9191659. doi: 10.1155/2022/9191659. eCollection 2022.
2
Immune Checkpoint Inhibitor Combination Therapy for Renal Cell Carcinomas With Concomitant Inferior Vena Cava Thrombi.免疫检查点抑制剂联合治疗合并下腔静脉癌栓的肾细胞癌。
In Vivo. 2022 Mar-Apr;36(2):1030-1034. doi: 10.21873/invivo.12798.
3
Outcomes of renal cell carcinoma with associated venous tumor thrombus: experience from a large cohort and short time span in a single center.
伴有静脉瘤栓的肾细胞癌的治疗结果：来自单一中心的大样本量和短时间跨度的经验。
BMC Cancer. 2021 Jul 2;21(1):766. doi: 10.1186/s12885-021-08508-x.
4
Impact of Primary Tumor Size on Prognosis in Patients With Metastatic Renal Cell Carcinoma Receiving Cytoreductive Nephrectomy: A Population Study of a Chinese Center and the US SEER Database.原发肿瘤大小对接受细胞减灭性肾切除术的转移性肾细胞癌患者预后的影响：中国中心和美国 SEER 数据库的人群研究。
Technol Cancer Res Treat. 2021 Jan-Dec;20:15330338211019507. doi: 10.1177/15330338211019507.
5
Tumor Stage and Substage Predict Cancer-specific Mortality After Nephrectomy for Nonmetastatic Renal Cancer: Histological Subtype-specific Validation.肿瘤分期和亚分期可预测非转移性肾癌肾切除术后的癌症特异性死亡率：组织学亚型特异性验证。
Eur Urol Focus. 2022 Jan;8(1):182-190. doi: 10.1016/j.euf.2021.02.009. Epub 2021 Feb 27.
6
Staging of renal cell carcinoma: current progress and potential advances.肾细胞癌的分期：当前进展与潜在进展。
Pathology. 2021 Jan;53(1):120-128. doi: 10.1016/j.pathol.2020.08.007. Epub 2020 Oct 26.
7
Impact of pathologic lymph node-positive renal cell carcinoma on survival in patients without metastasis: Evidence in support of expanding the definition of stage IV kidney cancer.病理淋巴结阳性的肾细胞癌对无转移患者生存的影响：支持扩大 IV 期肾癌定义的证据。
Cancer. 2020 Jul 1;126(13):2991-3001. doi: 10.1002/cncr.32912. Epub 2020 Apr 24.
8
Cytoreductive nephrectomy in patients with metastatic renal cell carcinoma and venous thrombus-Trends and effect on overall survival.细胞减灭性肾切除术治疗转移性肾细胞癌合并静脉血栓形成的患者：趋势及对总生存的影响。
Urol Oncol. 2019 Sep;37(9):577.e9-577.e16. doi: 10.1016/j.urolonc.2019.03.009. Epub 2019 Mar 28.
9
Complete response of renal cell carcinoma vena cava tumor thrombus to neoadjuvant immunotherapy.肾细胞癌静脉癌栓完全缓解对新辅助免疫治疗的反应。
J Immunother Cancer. 2019 Mar 11;7(1):66. doi: 10.1186/s40425-019-0546-8.
10
Grading of renal cell carcinoma.肾细胞癌分级。
Histopathology. 2019 Jan;74(1):4-17. doi: 10.1111/his.13735.